Enhancing the Therapeutic Activity of Hyperimmune IgG Against Chikungunya Virus Using FcγRIIIa Affinity Chromatography

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2023 May 30

PMID 37251375

Authors

Julie M Fox

Vicky Roy

Bronwyn M Gunn

Glen R Bolton

Daved H Fremont

Galit Alter

Michael S Diamond

Austin W Boesch

Affiliations

Soon will be listed here.

Abstract

Introduction: Chikungunya virus (CHIKV) is a re-emerging mosquito transmitted alphavirus of global concern. Neutralizing antibodies and antibody Fc-effector functions have been shown to reduce CHIKV disease and infection in animals. However, the ability to improve the therapeutic activity of CHIKV-specific polyclonal IgG by enhancing Fc-effector functions through modulation of IgG subclass and glycoforms remains unknown. Here, we evaluated the protective efficacy of CHIKV-immune IgG enriched for binding to Fc-gamma receptor IIIa (FcγRIIIa) to select for IgG with enhanced Fc effector functions.

Methods: Total IgG was isolated from CHIKV-immune convalescent donors with and without additional purification by FcγRIIIa affinity chromatography. The enriched IgG was characterized in biophysical and biological assays and assessed for therapeutic efficacy during CHIKV infection in mice.

Results: FcγRIIIa-column purification enriched for afucosylated IgG glycoforms. In vitro characterization showed the enriched CHIKV-immune IgG had enhanced human FcγRIIIa and mouse FcγRIV affinity and FcγR-mediated effector function without reducing virus neutralization in cellular assays. When administered as post-exposure therapy in mice, CHIKV-immune IgG enriched in afucosylated glycoforms promoted reduction in viral load.

Discussion: Our study provides evidence that, in mice, increasing Fc engagement of FcγRs on effector cells, by leveraging FcγRIIIa-affinity chromatography, enhanced the antiviral activity of CHIKV-immune IgG and reveals a path to produce more effective therapeutics against these and potentially other emerging viruses.

Citing Articles

Interaction of the endogenous antibody response with activating FcγRs enhance control of Mayaro virus through monocytes.

Dunagan M, Dabilla N, McNinch C, Brenchley J, Dolan P, Fox J PLoS Pathog. 2025; 21(2):e1012944.

PMID: 39993025 PMC: 11884725. DOI: 10.1371/journal.ppat.1012944.

Antibody-mediated control mechanisms of viral infections.

Mackin S, Sariol A, Diamond M Immunol Rev. 2024; 328(1):205-220.

PMID: 39162394 PMC: 11661935. DOI: 10.1111/imr.13383.

Activating FcγRs on monocytes are necessary for optimal Mayaro virus clearance.

Dunagan M, Dabilla N, McNinch C, Brenchley J, Dolan P, Fox J bioRxiv. 2024; .

PMID: 39149309 PMC: 11326306. DOI: 10.1101/2024.07.23.604823.

References

Braster R, Bogels M, Benonisson H, Wuhrer M, Plomp R, Bentlage A . Afucosylated IgG Targets FcγRIV for Enhanced Tumor Therapy in Mice. Cancers (Basel). 2021; 13(10). PMC: 8156657. DOI: 10.3390/cancers13102372. View

Winkler E, Gilchuk P, Yu J, Bailey A, Chen R, Chong Z . Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection. Cell. 2021; 184(7):1804-1820.e16. PMC: 7879018. DOI: 10.1016/j.cell.2021.02.026. View

Schilte C, Staikowsky F, Staikovsky F, Couderc T, Madec Y, Carpentier F . Chikungunya virus-associated long-term arthralgia: a 36-month prospective longitudinal study. PLoS Negl Trop Dis. 2013; 7(3):e2137. PMC: 3605278. DOI: 10.1371/journal.pntd.0002137. View

Fox J, Long F, Edeling M, Lin H, van Duijl-Richter M, Fong R . Broadly Neutralizing Alphavirus Antibodies Bind an Epitope on E2 and Inhibit Entry and Egress. Cell. 2015; 163(5):1095-1107. PMC: 4659373. DOI: 10.1016/j.cell.2015.10.050. View

Broeckel R, Fox J, Haese N, Kreklywich C, Sukulpovi-Petty S, Legasse A . Therapeutic administration of a recombinant human monoclonal antibody reduces the severity of chikungunya virus disease in rhesus macaques. PLoS Negl Trop Dis. 2017; 11(6):e0005637. PMC: 5491320. DOI: 10.1371/journal.pntd.0005637. View

Staples J, Breiman R, Powers A . Chikungunya fever: an epidemiological review of a re-emerging infectious disease. Clin Infect Dis. 2009; 49(6):942-8. DOI: 10.1086/605496. View

Brown E, Normandin E, Osei-Owusu N, Mahan A, Chan Y, Lai J . Microscale purification of antigen-specific antibodies. J Immunol Methods. 2015; 425:27-36. PMC: 4604017. DOI: 10.1016/j.jim.2015.06.005. View

Pinto A, Hassert M, Han X, Barker D, Carnelley T, Branche E . The Ability of Zika virus Intravenous Immunoglobulin to Protect From or Enhance Zika Virus Disease. Front Immunol. 2021; 12:717425. PMC: 8450494. DOI: 10.3389/fimmu.2021.717425. View

Hiatt A, Bohorova N, Bohorov O, Goodman C, Kim D, Pauly M . Glycan variants of a respiratory syncytial virus antibody with enhanced effector function and in vivo efficacy. Proc Natl Acad Sci U S A. 2014; 111(16):5992-7. PMC: 4000855. DOI: 10.1073/pnas.1402458111. View

10.

Couderc T, Khandoudi N, Grandadam M, Visse C, Gangneux N, Bagot S . Prophylaxis and therapy for Chikungunya virus infection. J Infect Dis. 2009; 200(4):516-23. PMC: 7109959. DOI: 10.1086/600381. View

11.

Tsetsarkin K, Higgs S, McGee C, de Lamballerie X, Charrel R, Vanlandingham D . Infectious clones of Chikungunya virus (La Réunion isolate) for vector competence studies. Vector Borne Zoonotic Dis. 2006; 6(4):325-37. DOI: 10.1089/vbz.2006.6.325. View

12.

Lachert E, Lasocka J, Bielawski A, Sulkowska E, Guz K, Pyrc K . Human Intramuscular Hyperimmune Gamma Globulin (hIHGG) Anti-SARS-CoV-2-Characteristics of Intermediates and Final Product. Viruses. 2022; 14(6). PMC: 9227433. DOI: 10.3390/v14061328. View

13.

Bournazos S, Klein F, Pietzsch J, Seaman M, Nussenzweig M, Ravetch J . Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity. Cell. 2014; 158(6):1243-1253. PMC: 4167398. DOI: 10.1016/j.cell.2014.08.023. View

14.

Davey Jr R, Fernandez-Cruz E, Markowitz N, Pett S, Babiker A, Wentworth D . Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial. Lancet Respir Med. 2019; 7(11):951-963. PMC: 6868512. DOI: 10.1016/S2213-2600(19)30253-X. View

15.

Hassan A, Shrihari S, Gorman M, Ying B, Yuan D, Raju S . An intranasal vaccine durably protects against SARS-CoV-2 variants in mice. Cell Rep. 2021; 36(4):109452. PMC: 8270739. DOI: 10.1016/j.celrep.2021.109452. View

16.

Bournazos S, DiLillo D, Goff A, Glass P, Ravetch J . Differential requirements for FcγR engagement by protective antibodies against Ebola virus. Proc Natl Acad Sci U S A. 2019; 116(40):20054-20062. PMC: 6778250. DOI: 10.1073/pnas.1911842116. View

17.

Borgherini G, Poubeau P, Jossaume A, Gouix A, Cotte L, Michault A . Persistent arthralgia associated with chikungunya virus: a study of 88 adult patients on reunion island. Clin Infect Dis. 2008; 47(4):469-75. DOI: 10.1086/590003. View

18.

Adams L, Leist S, Dinnon 3rd K, West A, Gully K, Anderson E . Fc-mediated pan-sarbecovirus protection after alphavirus vector vaccination. Cell Rep. 2023; 42(4):112326. PMC: 10063157. DOI: 10.1016/j.celrep.2023.112326. View

19.

Ackerman M, Moldt B, Wyatt R, Dugast A, McAndrew E, Tsoukas S . A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples. J Immunol Methods. 2011; 366(1-2):8-19. PMC: 3050993. DOI: 10.1016/j.jim.2010.12.016. View

20.

Jin J, Liss N, Chen D, Liao M, Fox J, Shimak R . Neutralizing Monoclonal Antibodies Block Chikungunya Virus Entry and Release by Targeting an Epitope Critical to Viral Pathogenesis. Cell Rep. 2015; 13(11):2553-2564. PMC: 4720387. DOI: 10.1016/j.celrep.2015.11.043. View